| Jul 30 |
TRACON Pharmaceuticals to wind down operations
|
| Jul 30 |
TRACON Pharmaceuticals Announces it Will Wind Down Operations
|
| Jul 2 |
Tracon mulls strategic options after sarcoma drug fails Phase II trial
|
| Jul 1 |
TRACON ends development of envafolimab, exploring strategic options
|
| Jul 1 |
TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform
|
| Jun 11 |
TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients
|
| May 15 |
Q1 2024 TRACON Pharmaceuticals Inc Earnings Call
|
| May 15 |
TRACON Pharmaceuticals Inc (TCON) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
|
| May 15 |
TRACON Pharmaceuticals, Inc. (TCON) Q1 2024 Earnings Call Transcript
|
| May 14 |
Tracon GAAP EPS of -$1.33 misses by $0.15, revenue of $0.1M
|
